

Applicants respectfully request entry of the foregoing amendments. Early and favorable action on the pending set of claims is earnestly solicited.

Respectfully submitted,

C.R.S.
Catherine Roseman Smith
Attorney for Applicant(s)
Registration No. 34,240

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, New Jersey 07601
(201) 487-5800
Date: August 10, 2001

U.S. PATENT AND TRADEMARK OFFICE
SEARCHED
INDEXED
MAILED
SERIALIZED
FILED
RECEIVED
JULY 10 2001
U.S. PATENT AND TRADEMARK OFFICE
SEARCHED
INDEXED
MAILED
SERIALIZED
FILED
RECEIVED
JULY 10 2001

Version with Markings to show Changes Made

Please amend the claims by adding underlined material and deleting bracketed material as follows:

4 (amended). A bacteriophage as claimed in [any one of claims 1 to 3] claim 1 which is a modified filamentous bacteriophage.

5 (amended). A bacteriophage as claimed in [any one of claims 1 to 4] claim 1 which is a modified M13 bacteriophage.

6 (amended). A bacteriophage as claimed in [any one of claims 1 to 5] claim 1 wherein said first component of said recombinant protein is derived from the protein responsible for adsorption of the unmodified form of said bacteriophage to bacterial pili.

7 (amended). A bacteriophage as claimed in [any one of claims 1 to 6] claim 1 wherein said second component of said recombinant protein comprises a ScFv polypeptide.

8 (amended). A bacteriophage as claimed in [any one of claims 1 to 7] which is a modified M13 bacteriophage wherein said first component of said recombinant protein is derived from the g3p protein.

10 (amended). A bacteriophage as claimed in [any one of claims 1 to 9] claim 1 for use in the treatment or prophylaxis of Helicobacter pylori infection wherein the antibody variable region sequences of said recombinant polypeptide are variable region sequences of a monoclonal antibody selected from the monoclonal antibodies of hybridoma cell lines 5F8 (ECACC No.95121524), 2H6 (ECACC No. 95121526) and 5D8 (ECACC No.95121527).

12 (amended). A pharmaceutical composition comprising a bacteriophage as claimed in [any one of the preceding claims] claim 1 in admixture with a pharmaceutically acceptable carrier or excipient.

13 (amended). A method for treatment of a bacterial infection in a mammal which comprises administering a bacteriophage of claim 1 to said mammal [or pharmaceutical composition according to any one of the preceding claims].

14 (amended). Use of a bacteriophage as claimed in [any one of claims 1 to 11] claim 1 in the manufacture of a medicament for the treatment or prophylaxis of a mucosal bacterial infection.